Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(9):1115–1118. doi: 10.1038/bjc.1997.520

Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia.

C S Mantzoros 1, A Tzonou 1, L B Signorello 1, M Stampfer 1, D Trichopoulos 1, H O Adami 1
PMCID: PMC2228109  PMID: 9365156

Abstract

Blood samples were collected from 52 incident cases of histologically confirmed prostate cancer, an equal number of cases of benign prostatic hyperplasia (BPH) and an equal number of apparently healthy control subjects. The three groups were matched for age and town of residence in the greater Athens area. Steroid hormones, sex hormone-binding globulin, and insulin-like growth factor 1 (IGF-1) were measured in duplicate by radioimmunoassay in a specialized US centre. Statistical analyses were performed using multiple logistical regression. The results for IGF-1 in relation to prostate cancer and BPH were adjusted for demographic and anthropometric factors, as well as for the other measured hormones. There was no relation between IGF-1 and BPH, but increased values of this hormone were associated with increased risk of prostate cancer; an increment of 60 ng ml(-1) corresponded to an odds ratio of 1.91 with a 95% confidence interval of 1.00-3.73. There was also some evidence for an interaction between high levels of testosterone and IGF-1 in relation to prostate cancer. This finding suggests that, in addition to testosterone, IGF-1 may increase the risk of prostate cancer in humans.

Full text

PDF
1115

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Angelloz-Nicoud P., Binoux M. Autocrine regulation of cell proliferation by the insulin-like growth factor (IGF) and IGF binding protein-3 protease system in a human prostate carcinoma cell line (PC-3). Endocrinology. 1995 Dec;136(12):5485–5492. doi: 10.1210/endo.136.12.7588299. [DOI] [PubMed] [Google Scholar]
  2. Burfeind P., Chernicky C. L., Rininsland F., Ilan J., Ilan J. Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci U S A. 1996 Jul 9;93(14):7263–7268. doi: 10.1073/pnas.93.14.7263. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Cohen P., Peehl D. M., Lamson G., Rosenfeld R. G. Insulin-like growth factors (IGFs), IGF receptors, and IGF-binding proteins in primary cultures of prostate epithelial cells. J Clin Endocrinol Metab. 1991 Aug;73(2):401–407. doi: 10.1210/jcem-73-2-401. [DOI] [PubMed] [Google Scholar]
  4. Cohen P., Peehl D. M., Stamey T. A., Wilson K. F., Clemmons D. R., Rosenfeld R. G. Elevated levels of insulin-like growth factor-binding protein-2 in the serum of prostate cancer patients. J Clin Endocrinol Metab. 1993 Apr;76(4):1031–1035. doi: 10.1210/jcem.76.4.7682560. [DOI] [PubMed] [Google Scholar]
  5. Daughaday W. H. The possible autocrine/paracrine and endocrine roles of insulin-like growth factors of human tumors. Endocrinology. 1990 Jul;127(1):1–4. doi: 10.1210/endo-127-1-1. [DOI] [PubMed] [Google Scholar]
  6. Ezzat S., Melmed S. Clinical review 18: Are patients with acromegaly at increased risk for neoplasia? J Clin Endocrinol Metab. 1991 Feb;72(2):245–249. doi: 10.1210/jcem-72-2-245. [DOI] [PubMed] [Google Scholar]
  7. Geller J. Basis for hormonal management of advanced prostate cancer. Cancer. 1993 Feb 1;71(3 Suppl):1039–1045. doi: 10.1002/1097-0142(19930201)71:3+<1039::aid-cncr2820711423>3.0.co;2-h. [DOI] [PubMed] [Google Scholar]
  8. Geller J. Clinical review: 67: Approach to chemoprevention of prostate cancer. J Clin Endocrinol Metab. 1995 Mar;80(3):717–719. doi: 10.1210/jcem.80.3.7883821. [DOI] [PubMed] [Google Scholar]
  9. Goustin A. S., Leof E. B., Shipley G. D., Moses H. L. Growth factors and cancer. Cancer Res. 1986 Mar;46(3):1015–1029. [PubMed] [Google Scholar]
  10. Kanety H., Madjar Y., Dagan Y., Levi J., Papa M. Z., Pariente C., Goldwasser B., Karasik A. Serum insulin-like growth factor-binding protein-2 (IGFBP-2) is increased and IGFBP-3 is decreased in patients with prostate cancer: correlation with serum prostate-specific antigen. J Clin Endocrinol Metab. 1993 Jul;77(1):229–233. doi: 10.1210/jcem.77.1.7686915. [DOI] [PubMed] [Google Scholar]
  11. Kimura G., Kasuya J., Giannini S., Honda Y., Mohan S., Kawachi M., Akimoto M., Fujita-Yamaguchi Y. Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LNCaP, DU145, and PC-3 cells. Int J Urol. 1996 Jan;3(1):39–46. doi: 10.1111/j.1442-2042.1996.tb00628.x. [DOI] [PubMed] [Google Scholar]
  12. LeRoith D., Clemmons D., Nissley P., Rechler M. M. NIH conference. Insulin-like growth factors in health and disease. Ann Intern Med. 1992 May 15;116(10):854–862. doi: 10.7326/0003-4819-116-10-854. [DOI] [PubMed] [Google Scholar]
  13. Miglietta L., Barreca A., Repetto L., Costantini M., Rosso R., Boccardo F. Suramin and serum insulin-like growth factor levels in metastatic cancer patients. Anticancer Res. 1993 Nov-Dec;13(6B):2473–2476. [PubMed] [Google Scholar]
  14. Montie J. E., Pienta K. J. Review of the role of androgenic hormones in the epidemiology of benign prostatic hyperplasia and prostate cancer. Urology. 1994 Jun;43(6):892–899. doi: 10.1016/0090-4295(94)90163-5. [DOI] [PubMed] [Google Scholar]
  15. Pietrzkowski Z., Mulholland G., Gomella L., Jameson B. A., Wernicke D., Baserga R. Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res. 1993 Mar 1;53(5):1102–1106. [PubMed] [Google Scholar]
  16. Webster N. J., Resnik J. L., Reichart D. B., Strauss B., Haas M., Seely B. L. Repression of the insulin receptor promoter by the tumor suppressor gene product p53: a possible mechanism for receptor overexpression in breast cancer. Cancer Res. 1996 Jun 15;56(12):2781–2788. [PubMed] [Google Scholar]
  17. Weiderpass E., Gridley G., Persson I., Nyrén O., Ekbom A., Adami H. O. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer. 1997 May 2;71(3):360–363. doi: 10.1002/(sici)1097-0215(19970502)71:3<360::aid-ijc9>3.0.co;2-w. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES